PERFORMANCE AND QUALITY MEASURES

2024 AHA/ASA Performance and Quality Measures for Spontaneous Intracerebral Hemorrhage: A Report From the American Heart Association/American Stroke Association

Writing Group Members

Ilana M. Ruff, MD, MS, Chair; Adam de Havenon, MD, MSCI, Vice Chair; Deborah L. Bergman, MS, FNP, FAHA; Rachelle Dugue, MD, PhD; Jennifer A. Frontera, MD; Joshua N. Goldstein, MD, PhD, FAHA; J. Claude Hemphill, MD, MAS, FAHA; Erika Marulanda-Londono, MD, MS; Shyam Prabhakaran, MD, MS, FAHA; Christopher T. Richards, MD, MS; N. Abimbola Sunmonu, MD, PhD; Paul Vilar, RN, MSN; Stacey Q. Wolfe, MD

AHA Stroke Performance Measures Oversight Committee

Daniel P. Gibson, MD, Chair; Adam de Havenon, MD, MSCI, Vice Chair; Salvador Cruz-Flores, MD, MPH, FAHA; Koto Ishida, MD, FAHA; Eva A. Mistry, MD, MSc, FAHA; Amre Nouh, MD, MBA, FAHA; Jennifer Rasmussen-Winkler, MD, FAHA; Paul Vilar, RN, MSN

New Quality Measures for ICH	
CT head	Within 25 minutes
BP Treatment	Initiated within 1 hour, reached target within 2 hours
Reversal	Anticoagulation reversal within 90 minutes
CTA/MRA	For patients with lobar hemorrhage, or deep hemorrhage in patients <
	45-year-old or no history of HTN
DSA	For patients with isolated IVH, with no ICH component